We reported previously that intravenous infu sion of atriopeptin increases blood flow to the choroid plexus. The first goal of this study was to determine whether blood-borne atriopeptin increases the production of CSF. Ventriculocisternal perfusion was used to mea sure the production of CSF in anesthetized rabbits. Atrio peptin increased blood flow to the choroid plexus (mea sured with microspheres) but did not alter the production of CSF. The second goal of the study was to determine
Atriopeptin may play an important role in the modulation of renal function and regulation of body fluids. There are receptors for atriopeptin on mi crovessels (Bianchi et aI., 1987) and epithelium (Bi anchi et aI., 1987; Steardo and Nathanson, 1987) of the choroid plexus. Receptor occupancy is associ ated with an increase in production of guanosine-3,5-monophosphate (cyclic GMP) (Steardo and Nathanson, 1987; Tsutsumi et aI., 1987) . The num ber of atriopeptin receptors in the choroid plexus changes in response to dehydration (Saavedra et aI., 1987) and hydrocephalus (Tsutsumi et aI., 1988) , which suggests that atriopeptin may play a role in the function of the choroid plexus.
We have shown previously that intravenous infu sion of atriopeptin increases blood flow to the cho roid plexus (Schalk et aI., 1989) . Because changes in blood flow to the choroid plexus may alter the production of eSF (eserr, 1974; Rapoport, 1976) , we anticipated that atriopeptin may increase the rate of production of eSF. The first goal of this whether intracerebroventricular injection of atriopeptin affects the production of CSF. Injection of atriopeptin into the cerebral ventricles increased blood flow to the choroid plexus but produced a small decrease in produc tion of CSF. In summary, blood-borne and intraventric ular atriopeptin increase blood flow to the choroid plexus, but do not increase the production of CSF. Key Words: Choroid plexus-CSF-Atrial natriuretic peptide-Mi crospheres. study was to determine whether blood-borne atrio peptin increases the production of eSF. We also tested the possibility that an increase in production of eSF would be more evident if baseline eSF pro duction were reduced. Thus, we examined re sponses to atriopeptin when baseline production of eSF was reduced by infusion of arginine vaso pressin.
Injection of atriopeptin into the cerebral ventri cles has been reported to decrease the production of eSF (Steardo and Nathanson, 1987) . This response might not be predicted in light of our previous find ing that blood-borne atriopeptin increases blood flow to the choroid plexus. Thus, the second goal of the study was to examine the effects of intraven tricular injection of atriopeptin on blood flow to the choroid plexus and on production of eSF.
METHODS
New Zealand white rabbits (n = 61, 3.0--4 .0 kg) were used for these experiments. The rabbits were deprived of water for 12 h before they were anesthetized with sodium pentobarbital (30 mg kg -I i. v .). Supplemental anesthetic was administered continuously (10-15 mg kg-1 i.v.) for the duration of each experiment. The trachea was cannu lated and rabbits were ventilated mechanically with room air that was supplemented with oxygen. Paralysis of skel etal muscle was produced with gallamine triethiodide (5 mg kg-1 i.v.).
A femoral artery was cannulated to monitor arterial blood pressure and for withdrawal of arterial blood sam ples for measurement of blood gases, pH, and plasma atriopeptin concentration. Both femoral veins were can nulated for infusion of drugs and supplemental anesthetic.
Blood flow was measured with microspheres of 15 ± 3 f.lm diameter, labeled with 46SC, 153Gd, l\3Sn, 85Sr, or 141Ce. Before injection, micro spheres were shaken vigor ously for several minutes. Approximately 1 x 106 micro spheres were injected into the left atrium over 15-20 s. Withdrawal of arterial blood began 15 s prior to the in jection of microspheres, and was continued for 90 s after the injection of microspheres. Blood was withdrawn from axillary arteries at a rate of 1.0 ml min -1 with a Harvard withdrawal pump. We have previously examined the va lidity of using microspheres to measure blood flow to the choroid plexus in rabbits (Faraci et aI., 1988) .
At the end of the blood flow experiments, anesthetized rabbits were killed with i. v. KCI. Tissues were removed and placed in buffered formalin. The choroid plexus from both lateral ventricles was combined for gamma counting. Choroid plexus from the fourth ventricle was also taken. The radioactivity of reference arterial blood samples and tissue samples was counted in a 3 in. NaI well gamma counter (Beckman 300, Beckman, Irvine, CA, U.S.A.), and isotope separation was performed with standard tech niques. Blood flow was calculated as BF = (C I x 100 x Qr)/Cr, where Qr is the reference sample flow rate, and Ct and Cr are counts in tissue and reference samples, respec tively. Blood flow is expressed as ml min-1 100 g-l.
Production of CSF was measured using a ventriculocis ternal perfusion technique similar to that described pre viously (Davson and Segal, 1970; Lindvall et aI., 1979) . Rabbits were placed in a head holder in a sphinx position. A burr hole was drilled over the right parietal cortex 1.0 cm caudal to the bregma and 0.75 cm lateral to the sagittal suture. A 25-gauge needle was lowered 0.7 cm through the burr hole into the lateral ventricle using a microma nipulator. A double-bore needle was used for experi ments involving intracerebroventricular injections. A catheter was inserted into the cisterna magna.
Artificial CSF was prepared as described previously (Sadoshima et aI., 1981) . Artificial CSF containing a non diffusable dye (blue dextran, molecular weight of 2 mil lion) was infused into the lateral ventricle at a rate of 30 f.ll min -I. The effluent was collected from the cisterna magna at lO-min intervals with a fraction collector and the concentration of dye in the CSF that was infused and collected was measured using a spectrophotometer. Ar tificial CSF containing dye was infused for 90-120 min prior to the control measurements to allow sufficient time for the dye to distribute by bulk flow throughout the CSF and achieve a steady state. The rate of CSF production (CSF) can be calculated as CSF = V (Cj -Co)/Co, where V = rate of infused CSF, Cj = concentration of dye in infused CSF, and Co = concentration of dye in collected CSF. A standard curve using known concentrations of blue dextran was prepared for each experiment.
Arterial blood samples were withdrawn for the deter mination of plasma concentrations of atriopeptin. Blood samples were collected in chilled tubes containing 15 mg ml-1 of ethylenediaminetetraacetate (EDT A). The blood was centrifuged and the serum was frozen at -70°C in polypropylene tubes until extraction. Atriopeptin was ex tracted on solid phase by use of C18 cartridges (Sep-Pak, Waters Associates, Milford, MA, U.S.A.) according to J Cereb Blood Flow Metab. Vol. 12, No.4, 1992 the method described by Gibbs (1984) . Recovery of un labeled atriopeptin from plasma using this method was 81% and was found to be uniform (r = 0.98). Atriopeptin was determined by radioimmunoassay with rabbit antise rum generated against human ANF-28 (Peninsula Labo ratories, Belmont, CA, U.S.A.). The minimal detectable amount in this assay averaged 2.6 ± 0.8 pg, while the ED 5 0 was 16.2 ± 3.1 pg (mean ± SD). The intra-assay coefIicient of variation averaged 5.1 % and the interassay variation was 14.1%.
Experimental protocols
In preliminary experiments, we attempted to measure blood flow and production of CSF in the same animal. However, the long duration of animal preparation and the experimental protocol was associated with instability in hemodynamic variables and values of CSF production in some rabbits. Thus, we shortened the duration time by preparing individual rabbits for either measurement of CSF production or measurement of blood flow.
In the first series of rabbits, the effect of prolonged intravascular infusion of atriopeptin on blood flow to the choroid plexus was examined. Blood flow was measured in 10 rabbits during control conditions and after 45 and 90 min of infusion of atriopeptin (75 ng kg -1 min -1 i. v.). In a previous study (Schalk et aI., 1989) , we examined re sponses to infusion of 220 ng kg -1 min -1 i. v. for 10 min.
In a second series of rabbits, we examined the effect of blood-borne atriopeptin on the rate of production of CSF. Ventriculocisternal perfusion was performed in 19 rab bits. An equilibration period of 120 min was followed by a 30-min control period. Ten rabbits then received an infusion of atriopeptin (75 ng kg -I min -1 i. v.) and 9 rab bits received vehicle (saline i. v.) for 90 min.
In a third series of animals, we examined the effects of atriopeptin on the production of CSF when production of CSF is reduced. Ventriculocisternal perfusion was per formed in 10 animals. After an equilibration period of 90 min, arginine vasopressin was infused (2 mU kg-I min-I i.v.) for 3.5 h. After infusion of arginine vasopressin for 30 min, measurements were obtained during a 30-min control period (during infusion of vasopressin). Infusion of vasopressin was continued, and animals then received either an infusion of atriopeptin (75 ng kg -I min -I i. v.; n = 5) or vehicle (Ringers lactate i.v.; n = 5) for 150 min.
In a fourth series of rabbits, we determined the effect of intracerebroventricular (i.c. v.) administration of atrio peptin on the rate of production of CSF. A needle was inserted into a lateral ventricle for the injection of drugs. Ventriculocisternal perfusion was performed in 15 rab bits. An equilibration period of 120 min was followed by a control period of 30 min. We injected atriopeptin (60 pmol in two rabbits and 600 pmol in seven rabbits) in artificial CSF (containing 1 mg ml-1 of blue dextran) into the lateral ventricle. Responses to the two doses were similar, so the data were pooled. Atriopeptin (60 pmolllO f.ll) was injected at a rate of 10 f.ll min -I. In six rabbits, vehicle (CSF with 1 mg ml-I of blue dextran) was in jected into the lateral ventricle at a rate of 10 f.ll min -I for 10 min.
In the last series of rabbits, we examined the effects of i.c.v. injection of atriopeptin on blood flow to the choroid plexus. Blood flow was measured in seven rabbits during control conditions and 45 and 90 min after beginning a lO-min infusion of atriopeptin (600 pmol i.c. v.).
Statistics
A one-way analysis of variance was performed on val ues for blood flow. Follow-up tests consisted of paired Student's t tests with a Bonferonni adjustment for multi ple comparisons.
An average value for CSF production during the 30-min control period was obtained and compared to an average value for the middle 30 min (45-min time point) and the last 30 min of infusion of atriopeptin or vehicle. The con trol period for animals that received vasopressin was the 30-min interval prior to infusion of atriopeptin or vehicle. A paired Student's t test was used for this comparison. A test for normality was performed on all data and, when values were not distributed normally, a natural log trans formation of data was used.
RESULTS

Effect of blood-borne atriopeptin
Blood flow. The plasma concentration of atrio peptin increased about 20-fold during infusion of atriopeptin (Table O. Blood flow to the choroid plexus increased during infusion of atriopeptin for 90 min ( Table l) . The increase in blood flow occurred despite a small de crease in arterial pressure. In contrast, blood flow to the masseter muscle remained constant during the 90-min infusion of atriopeptin. Arterial blood gases and pH did not change significantly during the experiment.
We have shown previously that blood flow to the choroid plexus is stable during repeated measure ments under control conditions or following infu sion of vehicle (Faraci et al., 1988; Maktabi et al., 1991) .
Production of cerebrospinal fluid. Plasma atrio peptin was 55 ± 36 pg ml-1 (mean ± SD) before infusion of vehicle and 55 ± 21 pg ml-I before in fusion of atriopeptin. After infusion of vehicle or atriopeptin for 90 min, plasma atriopeptin was 58 ± 31 and 1,424 ± 627 pg ml-1, respectively. Responses to intravenous infusion of atriopeptin (75 ng kg -1 min -I) for 90 min. Blood pH, Pco2 (mm Hg), and P02 (mm Hg) were 7.43 ± 0.06, 33 ± 3, and 129 ± 27, respectively, before infusion of atriopeptin. They did not change during infusion.
Values are mean ± SD; n = 10. * p < 0.05 compared to control.
Atriopeptin had minimal effects on the rate of production of CSF (Fig. l) . Arterial pressure and blood gases did not change during the experimental period except that the systemic pressure decreased slightly from 86 ± 9 to 76 ± 15 mm Hg after 90 min of infusion of atriopeptin.
Atriopeptin did not increase production of CSF when baseline values for production of CSF were reduced by infusion of vasopressin (Fig. 2) . In ex periments in which production of CSF was reduced with vasopressin ( Fig. 2) , plasma atriopeptin was 48 ± 28 pg ml-I before infusion of vehicle and 119 ± 112 pg ml-I before infusion of atriopeptin. After infusion of vehicle or atriopeptin for 90 min, plasma atriopeptin was 47 ± 50 and 2,060 ± 1,170 pg ml-1, respectively. The systemic arterial pressure and ar terial blood gases did not change during the exper imental period except for the systemic pressure, which decreased from 82 ± 8 to 65 ± 6 mm Hg after 90 min of infusion of atriopeptin.
Effect of intracerebroventricular atriopeptin
Blood flow. Injection of atriopeptin into the cere bral ventricles did not increase plasma levels of atriopeptin (Table 2 ) and did not affect arterial pres sure (Table 2 ). Blood flow to the choroid plexus, however, was significantly elevated 45 min after the injection. Changes in blood flow were similar in choroid plexus from the fourth and lateral ventricles (Table 2) , which suggests that atriopeptin was dis tributed throughout the ventricular system. Blood flow to the masseter muscle was not significantly changed.
Production of cerebrospinal fluid. Production of CSF did not change in the rabbits in which vehicle was injected i. c. v. Injection of atriopeptin into the cerebral ventricles decreased CSF production by 22 CSF Production (, .. d/min) ± 17% (p < 0.05; Fig. 3) . The systemic arterial pressure and blood gases did not change during the experimental period. In these experiments, injec tion of atriopeptin into the cerebral ventricles did not increase plasma levels of atriopeptin. Plasma levels of atriopeptin were 53 ± 20 and 48 ± 22 pg ml-I before and 90 min after injection of vehicle, respectively, and 77 ± 20 and 62 ± 9 pg ml-1 before and 90 min after injection of atriopeptin, respec tively.
DISCUSSION
There are two major findings in this study. First, blood-borne atriopeptin increases blood flow to the choroid plexus, but does not increase the rate of production of CSF under normal conditions or Blood pH, Pe02 (mm Hg), and P02 (mm Hg) were 7.44 ± 0.05, 34 ± 2, and 132 ± 22, respectively, before injection of atriopeptin. These values did not change during the experimental period except that P02 was 143 ± 20* at 90 min.
Values are mean ± SD; n = 7. The starred bracket represents a significant difference when comparing the average value for CSF production during the 30-min control period to the average value for the last 30 min of infusion of atriopeptin.
when baseline CSF production is reduced by vaso pressin. Second, i. c.v. atriopeptin increases blood flow to the choroid plexus, but decreases the rate of production of eSF.
Effect of blood-borne atriopeptin
The dose of atriopeptin that was injected intrave nously produced plasma concentrations in arterial blood that are at least twofold higher than the max imum concentrations that have been observed in venous blood in pathophysiological states (Wam back et aI., 1987; Allen et aI., 1989) . Atriopeptin concentrations measured in arterial blood, how ever, may be as much as 50% higher than concen trations measured in venous blood (Schutten et aI., 1987) . Thus, the levels of atriopeptin that were achieved in this study were comparable to or greater than the maximal levels observed under pathophysiological conditions.
Atriopeptin increased blood flow to the choroid plexus. In a previous study, we measured blood flow after intravenous infusion of the same dose of atriopeptin (75 ng kg-I min -I) for 10 min and found no significant increase in blood flow to the choroid plexus (Schalk et aI., 1989) . The plasma levels of atriopeptin in response to this dose of atriopeptin were comparable in the two studies. Thus, it ap pears that atriopeptin does not exert its maximal effect on blood flow to the choroid plexus in 10 min.
Blood-borne atriopeptin did not affect the rate of production of CSF, despite an increase in blood flow to the choroid plexus. Thus, it appears that blood-borne atriopeptin does not normally affect the production of CSF. We considered the possibil ity that atriopeptin may play a role when the pro-duction of CSF is reduced. Atriopeptin, however, did not increase the production of CSF even when baseline values for production of CSF were reduced by infusion of vasopressin.
Blood-borne atriopeptin produced a small de crease in arterial pressure, which may have pro duced a modest increase in sympathetic neural dis charge. Sympathetic stimulation decreases the pro duction of CSF (Lindvall et aI., 1977; Lindvall and Owman, 1981) . Thus, it is possible that an increase in CSF production induced by atriopeptin was masked by enhanced sympathetic output. We can not exclude this possibility, but believe it is un likely. Blood flow to the choroid plexus increased during atriopeptin infusion, and sympathetic stimu lation decreases blood flow to the choroid plexus (AIm and Bill, 1973) . Thus, direct effects of atrio peptin on the choroid plexus appear to be greater than effects of sympathetic activity during reduc tion in arterial pressure by atriopeptin.
Effect of intracerebroventricular atriopeptin
Injection of atriopeptin into the cerebral ventri cles of conscious rabbits has been reported to pro duce a 35% decrease in production of CSF (Steardo and Nathanson, 1987) . Because we found that blood-borne atriopeptin did not affect the produc tion of CSF in anesthetized rabbits, it seemed im portant to determine whether the route of adminis tration influenced responses to atriopeptin. We found that i.c. v. administration of atriopeptin pro duced a 22 ± 17% decrease in production of CSF in anesthetized rabbits. These results are in agreement with previous findings in conscious rabbits (Steardo and Nathanson, 1987) .
We considered the possibility that the decrease in CSF production in response to injection of atriopep tin into the cerebral ventricles may be due, at least in part, to a decrease in blood flow to the choroid plexus. Blood flow to the choroid plexus was ele vated, however, 45 min after administration of atriopeptin into the cerebral ventricles. Thus, the decrease in rate of production of CSF occurred de spite an increase in blood flow to the choroid plexus. Atriopeptin may have direct effects on cho roid epithelium to decrease the production of CSF. Secretion of CSF depends in part upon Na + trans port across choroidal epithelial cells (Johanson, 1988) , and atriopeptin decreases transport of Na + in the choroid plexus in vitro (Johanson et aI., 1990) .
It is not clear what mechanisms account for the observation that i.c. v. atriopeptin decreased the production of CSF while blood-borne atriopeptin had no effect. In the kidney, atriopeptin activates guanylate cyclase (Zeidel et aI., 1987) and inhibits Na + transport in inner medullary collecting duct cells (Zeidel et aI., 1988) . Guanylate cyclase-linked receptors for atriopeptin on choroidal epithelial cells have not been localized to the apical (CSF) or basal (blood) side of the cell. Tight junctions are present between epithelial cells of the choroid plexus (Johanson, 1988) , which presumably restrict diffusion of atriopeptin between the apical and basal sides of the epithelial cell. If guanylate cyclase linked receptors for atriopeptin are located only on the apical side of the epithelial cells, the location of these receptors could explain the finding that i.c.v. atriopeptin affected the production of CSF while blood-borne atriopeptin had no effect. A second ex planation for the finding that blood-borne atriopep tin had no effect on production of CSF while i. c. v. atriopeptin affected production of CSF is that the concentration of atriopeptin to which epithelial cells were exposed was probably much greater with i.c. v. administration of atriopeptin.
Because diffusion of atriopeptin across the epi thelial barrier of the choroid plexus presumably is limited, it is surprising that atriopeptin injected into the cerebral ventricles reached vascular muscle and produced an increase in blood flow to the choroid plexus. It is unclear, however, whether the epithe lial barrier in the choroid plexus extends to choroi dal resistance vessels. We speculate that these ves sels may not be enclosed by epithelial cells, and may be separated from CSF only by pia mater, which may not present a barrier for diffusion of atriopeptin.
The physiological importance of elevated levels of atriopeptin in CSF is not clear. The concentra tion of atriopeptin in CSF is low under normal con ditions (Broderick et aI., 1987; Marumo et aI., 1987; Masuda et aI., 1988) , and it does not correlate with plasma levels (Broderick et aI., 1987; Masuda et aI. , 1988) , which suggests a neuronal source (Broderick et aI., 1987; Marumo et aI., 1987; Masuda et aI., 1988) . Atriopeptin may be a neurotransmitter in several nuclei associated with modulation of cardio vascular function (Jacobowitz et aI., 1985; Saper and Standaert, 1985; Standaert and Saper, 1988) , so that local concentrations of atriopeptin may in crease substantially. Elevated levels of atriopeptin in CSF have been reported after subarachnoid hem orrhage (Doczi et aI., 1988) and in patients with various neurological disorders (Levin, 1988) . It is not clear whether the elevated levels of atriopeptin are a result of tissue damage and simply a concur rent event of hemorrhage, or whether atriopeptin may play a protective role by decreasing the pro duction of CSF.
